InvestSMART

Price-sensitive announcement not found.

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

ALERT: Price-sensitive ASX Announcement for NSB
Current share price for NSB : $0.062 -0.073 (-54.07%)+
Announcement
Release
30 Jan 2026 8:27AM
Price at Release
$0.135
Full Release
download
Summary
NeuroScientific Biopharmaceuticals Limited (ASX:NSB) reported its financial and operational activities for the quarter ending 31 December 2025. The company is advancing its proprietary StemSmart™ platform for treating fistulising Crohn's Disease under the Therapeutic Goods Administration’s Special Access Scheme. This initiative is part of their preparation for a Phase 2 clinical trial. The company reported a strong cash position of approximately $6.4 million, with managed expenses and no net cash flow from investing or financing activities. Payments for research and development were about $315k, with staff and administration costs at $21k and $193k, respectively. The quarterly cash flow report indicated a net cash outflow in operating activities of $532k for the quarter. Additionally, NSB is progressing its manufacturing technology transfer to Q-Gen and preparing its supply chain for future clinical trials.
Key Points
  • StemSmart™ Special Access Program for Crohn's Disease is advancing.
  • Phase 2 Clinical Trial preparation is underway with real-world clinical data.
  • Appointment of a Clinical & Scientific Advisory Board to support development.
  • Technology transfer to Q-Gen for manufacturing readiness is progressing.
  • Strong financial position with cash and cash equivalents approximately $6.4 million.
  • Net cash outflow from operating activities was $532k for the quarter.
  • Research and development payments totaled approximately $315k.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.